Wanatpreeya Phongsamart1, Rawiwan Hansudewechakul2, Torsak Bunupuradah3, Virat Klinbuayaem4, Sirinya Teeraananchai3, Wisit Prasithsirikul5, Stephen J Kerr6, Noppadon Akarathum4, Sukanda Denjunta2, Jintanat Ananworanich7, Kulkanya Chokephaibulkit8. 1. Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 2. Chiangrai Prachanukroh Hospital, Chiangrai, Thailand. 3. The HIV Netherlands Australia Thailand Research Collaboration, the Thai Red Cross AIDS Research Center, Bangkok, Thailand. 4. Sanpatong Hospital, Chiangmai, Thailand. 5. Bamrasnaradura Infectious Disease Institute, Nonthaburi, Thailand. 6. The HIV Netherlands Australia Thailand Research Collaboration, the Thai Red Cross AIDS Research Center, Bangkok, Thailand; Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia. 7. The HIV Netherlands Australia Thailand Research Collaboration, the Thai Red Cross AIDS Research Center, Bangkok, Thailand; Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia; Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; SEARCH, The Thai Red Cross AIDS Research Center, Bangkok, Thailand. 8. Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Electronic address: sikch@mahidol.ac.th.
Abstract
OBJECTIVE: To describe the outcomes of antiretroviral therapy (ART) in a large cohort of HIV-infected children in Thailand. METHODS: The data were obtained from four collaborative referral sites around the country. Data from 2008 to March 2011 were collected prospectively, and data before 2008 were collected retrospectively. RESULTS: Of the 1139 children, 599 (52.6%) were female, and the duration of ART was a median 2.9 years (interquartile range (IQR) 3.3-5.5 years). At ART initiation, the median age was 7.1 years (IQR 3.4-10.0 years), CD4 percentage was 9.0% (IQR 3.0-17.0%), and 61.3% were in World Health Organization (WHO) stage 3 or 4. Seventy-four percent were initiated on an NNRTI-based regimen. The death and lost to follow-up rates were 1.3 (95% confidence interval (CI) 1.1-1.6) and 2.2 (95% CI 1.6-2.6)/100 patient-years of follow-up, respectively. At the last clinic visit of 919 children, the median CD4 percentage was 27.0% (IQR 23.0-32.0%) and 80.2% had HIV-RNA <40 copies/ml. WHO stage 1 or 2 at ART initiation was associated with having a viral load <40 copies/ml (p < 0.002), and baseline CD4 ≥15% and starting with a three-drug regimen were associated with achieving CD4 ≥25% (p<0.001). CONCLUSIONS: Although most children initiated ART at low CD4 levels, the majority achieved immune reconstitution and long-term virological control. Earlier treatment may improve these outcomes.
OBJECTIVE: To describe the outcomes of antiretroviral therapy (ART) in a large cohort of HIV-infectedchildren in Thailand. METHODS: The data were obtained from four collaborative referral sites around the country. Data from 2008 to March 2011 were collected prospectively, and data before 2008 were collected retrospectively. RESULTS: Of the 1139 children, 599 (52.6%) were female, and the duration of ART was a median 2.9 years (interquartile range (IQR) 3.3-5.5 years). At ART initiation, the median age was 7.1 years (IQR 3.4-10.0 years), CD4 percentage was 9.0% (IQR 3.0-17.0%), and 61.3% were in World Health Organization (WHO) stage 3 or 4. Seventy-four percent were initiated on an NNRTI-based regimen. The death and lost to follow-up rates were 1.3 (95% confidence interval (CI) 1.1-1.6) and 2.2 (95% CI 1.6-2.6)/100 patient-years of follow-up, respectively. At the last clinic visit of 919 children, the median CD4 percentage was 27.0% (IQR 23.0-32.0%) and 80.2% had HIV-RNA <40 copies/ml. WHO stage 1 or 2 at ART initiation was associated with having a viral load <40 copies/ml (p < 0.002), and baseline CD4 ≥15% and starting with a three-drug regimen were associated with achieving CD4 ≥25% (p<0.001). CONCLUSIONS: Although most children initiated ART at low CD4 levels, the majority achieved immune reconstitution and long-term virological control. Earlier treatment may improve these outcomes.
Authors: Emmanuel C Nwosu; Frances C Robertson; Martha J Holmes; Mark F Cotton; Els Dobbels; Francesca Little; Barbara Laughton; Andre van der Kouwe; Ernesta M Meintjes Journal: Metab Brain Dis Date: 2017-12-05 Impact factor: 3.584
Authors: Jason C Brophy; Michael T Hawkes; Edson Mwinjiwa; Gabriel Mateyu; Sumeet K Sodhi; Adrienne K Chan Journal: PLoS One Date: 2016-11-03 Impact factor: 3.240
Authors: Sophie Desmonde; Anne M Neilan; Beverly Musick; Gabriela Patten; Kulkanya Chokephaibulkit; Andrew Edmonds; Stephany N Duda; Karen Malateste; Kara Wools-Kaloustian; Andrea L Ciaranello; Mary-Ann Davies; Valériane Leroy Journal: J Int AIDS Soc Date: 2020-10 Impact factor: 5.396
Authors: Emmanuel C Nwosu; Martha J Holmes; Mark F Cotton; Els Dobbels; Francesca Little; Barbara Laughton; Andre van der Kouwe; Ernesta M Meintjes; Frances Robertson Journal: IBRO Neurosci Rep Date: 2021-02-10